| Summary: | Jennifer Donnan,1 Rita Huang,1 Laurie Twells2 1School of Pharmacy, Memorial University, St. John’s, Newfoundland and Labrador, Canada; 2Faculty of Medicine, Memorial University, St. John’s, Newfoundland and Labrador, CanadaCorrespondence: Jennifer Donnan, Tel +1 709 864-3587, Email Jennifer.donnan@mun.caPurpose: Obesity is a complex disease with negative impacts on physical and mental health. The treatment of obesity is an area where shared decision making and patient preferences play an important role. Recommendations surrounding weight loss medications are evolving and only recently, with the publication of the 2020 Canadian Obesity Management Clinical Guidelines, pharmacotherapy has become a recommended alternative for obesity management. Guidelines recommend three medications: orlistat, liraglutide, and naltrexone/bupropion. This study sought to identify medication attributes relevant to patients starting pharmacotherapy for weight management.Patients and Methods: Semi-structured focus groups and interviews were conducted with Canadian residents who were ≥ 18 years of age and were living with obesity (body mass index [BMI] ≥ 30kg/m2 or ≥ 27kg/m2 with adiposity-related complications). Sessions were conducted virtually, audio recorded, and transcribed. Two team members used a combination of inductive and deductive coding to independently code the data. A final coding template was agreed upon through discussion.Results: A total of 21 individuals participated (85.7% female, 76.2% ≥ 40 years of age) with the average BMI being 44.3 kg/m2. Participants touched upon many attributes which were categorized into five categories: 1) cost, 2) regimen, 3) side effects, 4) benefits, and 5) non-medication attributes. Cost of medications, lack of coverage by insurance companies, and stigma were identified as major barriers to accessing medications. There was consensus in the desire for a simple regimen, however there was heterogeneity among opinions on tolerability of side effects, desired benefits, and route of ...
|
|---|